Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics

STAMFORD, Conn., July 9, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) is requiring opioid analgesic companies to implement a new, shared Risk Evaluation & Mitigation Strategy (…
Read the full story: BioSpace.com Featured News